A preliminary study of intralesional, intralymph node, intravenous and intraperitoneal Corynebacterium parvum treatments in patients with advanced cancer

✍ Scribed by Vincent S. T. Cheng; Herman D. Suit; C. C. Wang; John Raker; Ernest Weymuller; Sheldon Kaufman

• Publisher: John Wiley and Sons
• Year: 1978
• Tongue: English
• Weight: 391 KB
• Volume: 42
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(197810)42:4<1912::aid-cncr2820420432>3.0.co;2-5

✦ Synopsis

Twenty-one patients with squamous cell carcinoma of oral cavity and/or cervical lymph node and four patients with soft tissue sarcomas were given intralesional (2-4 mg/mz) and intralymph node (2-4 mg/m2) C. parvum injections followed by 5 intravenous (2-4 mg/m2) C. parvum treatments and conventional therapies. Seven patients with Stage I11 ovarian carcinomas were given intraperitoneal (2 -4 mg/mz) C. parvum injections followed by conventional therapies. The local and systemic effects of the C. parvum treatments were described and the anti-tumor effects were evaluated in this series of patients. Cancer 42: 19 12 -19 15, 1978. PHASE I toxicity study of intravenously A (iv) administered C. parvum (2-4 mg/m2)

in patients with advanced cancer showed that the symptomatic side effects are predictable and can be controlled without significant morbidity within 5-7 hours by appropriately timed medication^.^ We have subsequently treated over 70 patients with C. paruum by different routes of administration on an out-patient basis without a major complication. This present report is an account of the local and systemic reactions of C. parvum given by intralesional (il), intralymph node (iln) plus iv routes in patients with advanced head and neck carcinomas and soft tissue sarcomas and intraperitoneal (ip) route in patients with advanced ovarian carcinomas.

Methods

Thirty-two patients with advanced cancer and previously untreated were accepted into